Patents by Inventor Pradeep Jayarajan
Pradeep Jayarajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11622967Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: GrantFiled: August 1, 2018Date of Patent: April 11, 2023Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Vijay Sidram Benade, Saivishal Daripelli, Pradeep Jayarajan, Jyothsna Ravula, Venkateswarlu Jasti
-
Publication number: 20230000859Abstract: The present invention provides a method for treating behavioral and psychological symptoms in patients with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising pure 5-HT6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in patients with dementia. The present invention further provides use of the said compounds in the manufacture of a medicament, and a pharmaceutical composition comprising the said compounds intended for the treatment of disorders described herein.Type: ApplicationFiled: December 2, 2020Publication date: January 5, 2023Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Veena REBALLI, Pradeep JAYARAJAN, Renny ABRAHAM, Venkateswarlu JASTI, Rajesh BADANGE, Vijay Sidram BENADE
-
Publication number: 20220409614Abstract: The present invention provides a method for treating behavioral and psychological symptoms in patient with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist, masupirdine or a pharmaceutically acceptable salt thereof either alone or in combination with an acetylcholinesterase inhibitor such as donepezil and NMDA (N-Methyl-D-aspartate) receptor antagonist, memantine. The present invention further provides use of the said compound in the manufacture of a medicament and pharmaceutical compositions comprising the said compounds intended for the treatment of the disorders described herein.Type: ApplicationFiled: December 2, 2020Publication date: December 29, 2022Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Satish JETTA, Raghava Chowdary PALACHARLA, Santosh Kumar PANDEY, Abdul Rasheed MOHAMMED, Vijay Sidram BENADE, Vinod Kumar GOYAL, Ramkumar SUBRAMANIAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 11458135Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: GrantFiled: August 3, 2016Date of Patent: October 4, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
-
Patent number: 11253514Abstract: The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: GrantFiled: August 3, 2016Date of Patent: February 22, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
-
Patent number: 11234979Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs).Type: GrantFiled: October 17, 2018Date of Patent: February 1, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Srinivas Ravella, Vanaja Middekadi, Vinod Kumar Goyal, Pradeep Jayarajan, Saivishal Daripelli, Venkateswarlu Jasti
-
Publication number: 20210386727Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4] oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: October 17, 2019Publication date: December 16, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Venkata Ramalingayya GRANDHI, Pradeep JAYARAJAN, Vijay BENADE, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20210338661Abstract: The present invention relates to new uses of a pure 5-HT6 receptor antagonist, specifically 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, vascular dementia, chemotherapy-induced cognitive impairment and behavioral changes in dementia such as agitation, aggression, depression, anxiety, psychosis, disinhibition, or sleep disturbances. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: June 29, 2018Publication date: November 4, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Venkata Ramalingayya GRANDHI, Pradeep JAYARAJAN, Venkateswarlu JASTI
-
Patent number: 11116764Abstract: The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.Type: GrantFiled: August 3, 2016Date of Patent: September 14, 2021Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
-
Publication number: 20210213026Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: August 1, 2018Publication date: July 15, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Vijay Sidram BENADE, Saivishal DARIPELLI, Pradeep JAYARAJAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 11040026Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: GrantFiled: August 31, 2017Date of Patent: June 22, 2021Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20200237761Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: ApplicationFiled: October 17, 2018Publication date: July 30, 2020Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed Rasheed MOHAMMED, Anil Karbhari SHINDE, Srinivas RAVELLA, Vanaja MIDDEKADI, Vinod Kumar GOYAL, Pradeep JAYARAJAN, Saivishal DARIPELLI, Venkateswarlu JASTI
-
Patent number: 10603323Abstract: The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.Type: GrantFiled: August 14, 2017Date of Patent: March 31, 2020Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Publication number: 20190343812Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: ApplicationFiled: August 31, 2017Publication date: November 14, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20190336509Abstract: The present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the 10 pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 14, 2017Publication date: November 7, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20190175586Abstract: The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 3, 2016Publication date: June 13, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
-
Publication number: 20190160075Abstract: The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 14, 2017Publication date: May 30, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20190160055Abstract: The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 3, 2016Publication date: May 30, 2019Applicant: Suven Life Sciences LimitedInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
-
Publication number: 20190125743Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: ApplicationFiled: August 3, 2016Publication date: May 2, 2019Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
-
Patent number: 9957257Abstract: The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.Type: GrantFiled: January 7, 2016Date of Patent: May 1, 2018Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Sangram Keshari Saraf, Narsimha Bogaraju, Ramkumar Subramanian, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti